Latest total liabilities for SEEL: $31M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Seelos Therapeutics (SEEL) currently reports a total liabilities of $31M as of June 2024. That compares with $59M in the prior-year period — down 48.3% year over year. Use the charts on this page to explore Seelos Therapeutics's total liabilities history and peer comparisons.
Seelos Therapeutics's total liabilities decreased from $59M to $31M — a 48.3% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Seelos Therapeutics reported $31M in total liabilities as of June 2024. That compares with $59M in the prior-year period — down 48.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Seelos Therapeutics, and consider following SEEL for alerts when major investors trade the stock.
Seelos Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SEEL with unrelated industries.